ArticleJournal of clinical hypertension (Greenwich, Conn.)2020
Urinary vanin-1 associated with chronic kidney disease in hypertensive patients: A pilot study.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Revealing VNN1: An Emerging and Promising Target for Inflammation and Redox Balance.Immunity, inflammation and disease · 2025Pooled it
- Biomarker potential of vanin-1-derived pantothenic acid in diabetes and its associated cardiovascular complications.Scientific reports · 2025Article
- Urinary vanin-1 as a novel biomarker for survival in peripheral artery disease.Vascular medicine (London, England) · 2024Article
- Urinary vanin-1, tubular injury, and graft failure in kidney transplant recipients.Scientific reports · 2024Article
- Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review.Diseases (Basel, Switzerland) · 2022Review
- Upregulated Vanins and their potential contribution to periodontitis.BMC oral health · 2022Article
- Emerging Biomarkers for Early Detection of Chronic Kidney Disease.Journal of personalized medicine · 2022Review
- Association of urinary vanin-1 with kidney function decline in hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Plasma Vanin-1 as a Novel Biomarker of Sepsis for Trauma Patients: A Prospective Multicenter Cohort Study.Infectious diseases and therapy · 2021Article
- Urinary vanin-1 and chronic kidney disease in hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Urinary vanin-1 associated with chronic kidney disease in hypertensive patients: A pilot study.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension and chronic kidney disease (CKD) are serious interrelated public health problems. Despite the monitoring and control of high blood pressure, symptoms of CKD are not usually apparent in its early stages. Previously, we reported the utility of urinary vanin-1 as an early biomarker of kidney injury in spontaneously hypertensive rats, but it remains unknown whether urinary vanin-1 is associated with CKD in humans. In this study, we estimated associations between urinary vanin-1 and parameters of kidney function in a cross-sectional study of hypertensive patients. We measured concentrations of vanin-1 using spot urine from 147 adult hypertensive patients (mean age, 72.8 years; 39.5% women). Patients were divided into 2 groups based on the median of the estimated glomerular filtration rate (eGFR). The group with eGFR < 60 mL/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.